Table 4 HR with 95% CI for PFS in patients with EGFR-mutant NSCLC and brain metastases.

From: First-line treatment of EGFR-mutated non-small cell lung cancer with brain metastases: a systematic review and meta-analysis

1G EGFR-TKIs

          

1.32 (0.63- 2.73)

2G EGFR-TKIs

         

2.11 (1.71–2.57)*

1.59 (0.75–3.40)

3G EGFR-TKIs

        

2.53 (1.77–3.61)*

1.92 (0.85–4.43)

1.21 (0.80–1.82)

1G EGFR-TKIs + CT

       

4.46 (2.57–7.72)*

3.39 (1.36–8.46)*

2.13 (1.28–3.54)*

1.76 (0.92–3.39)

3G EGFR-TKIs + CT

      

3.04 (1.83–5.05)*

2.31 (0.95–5.62)

1.45 (0.91–2.31)

1.20 (0.65–2.23)

0.68 (0.34–1.36)

3G EGFR-TKIs + EGFR-Met BsAb

     

1.72 (1.16–2.56)*

1.31 (0.57–3.01)

0.82 (0.53–1.28)

0.68 (0.40–1.16)

0.38 (0.20–0.76)*

0.57 (0.30–1.08)

1G EGFR-TKIs + VEGF mAb

    

2.53 (0.73–8.80)

1.92 (0.70–5.27)

1.21 (0.34–4.27)

1.00 (0.27–3.66)

0.57 (0.15–2.21)

0.83 (0.22–3.20)

1.47 (0.40–5.44)

2G EGFR-TKIs + VEGF mAb

   

2.52 (0.98- 6.47)

1.91 (0.58–6.31)

1.20 (0.48–3.02)

0.99 (0.36–2.73)

0.56 (0.20–1.62)

0.83 (0.29–2.33)

1.46 (0.52–4.07)

0.99 (0.21–4.75)

3G EGFR-TKIs + VEGF mAb

  

3.21 (1.72–6.00)*

2.44 (0.93–6.39)

1.53 (0.85–3.77)

1.27 (0.62–2.61)

0.72 (0.33–1.57)

1.06 (0.50–2.24)

1.87 (0.89–3.91)

1.27 (0.32–5.12)

1.28 (0.43–3.82)

3G EGFR-TKIs + VEGFR mAb

 

1.10 (0.54–2.22)

0.84 (0.30–2.30)

0.52 (0.25–1.09)

0.43 (0.20–0.95)*

0.25 (0.10–0.60)*

0.36 (0.15–0.86)*

0.64 (0.28–1.43)

0.43 (0.10–1.86)

0.43 (0.13–1.42)

0.34 (0.13–0.88)*

1G EGFR-TKIs + VEGFR TKI

  1. HR: hazard ratio; CI: confidence intervals; PFS: progression-free survival; NSCLC: non-small cell lung cancer; 1G/2G/3G EGFR-TKIs: first/second/third-generation epidermal growth factor receptor tyrosine kinase inhibitors; VEGF mAbs: vascular endothelial growth factor monoclonal antibodies; VEGFR mAbs: vascular endothelial growth factor receptor monoclonal antibodies; EGFR-MET BsAb: epidermal growth factor receptor-mesenchymal epithelial transition factor bispecific monoclonal antibodies; CT: chemotherapy.
  2. *Represents a statistically significant difference in HR values
Back to article page